Classement en actions
#41239
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Prix de l'action
$0.01156596
Capitalisation boursière
$32.34K
Changement (1 jour)
-5.56%
Changement (1 an)
-43.21%
Échange GENinCode plc (GENI)
Bénéfices pour GENinCode plc (GENI)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de GENinCode plc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour GENinCode plc de 2026 à 2026
Bénéfices à la fin de chaque année
| Année |
Bénéfices |
Changez |
|
Pas assez de données pour les dates fournies. |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise |
Bénéfices |
Différence de bénéfices |
Pays |
|
|
$7.61B |
-
|
US
|
|
|
$4.76B |
-
|
US
|
|
|
- |
-
|
CN
|
|
|
$1.42B |
-
|
US
|
|
|
$-252.70M |
-
|
US
|
